Loading clinical trials...
Loading clinical trials...
An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen
Conditions
Interventions
BIBW 2992
Locations
14
Belgium
1200.10.3201 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1200.10.3208 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1200.10.3203 Boehringer Ingelheim Investigational Site
Charleroi, Belgium
1200.10.3205 Boehringer Ingelheim Investigational Site
Ghent, Belgium
1200.10.3204 Boehringer Ingelheim Investigational Site
Leuven, Belgium
1200.10.3206 Boehringer Ingelheim Investigational Site
Wilrijk, Belgium
Start Date
November 1, 2006
Primary Completion Date
May 1, 2009
Last Updated
December 31, 2013
NCT07191730
NCT06797635
NCT06312176
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions